Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
This study measures the levels of circulating tumor DNA (ctDNA) in patients with stage II-III rectal cancer before, during, and after treatment to find out if the presence or absence of ctDNA in patient's blood using the Signatera test can be used to gauge how different treatments may affect rectal cancer. ctDNA is DNA from the rectal cancer that is circulating in the blood. The purpose of this study is to understand if the way rectal tumors respond to standard treatment can be associated with varying levels of ctDNA.
• Participant must provide written informed consent before any study-specific procedures or interventions are performed
• Participants aged \>= 18 years
• Pathologically-confirmed stage II or III primary adenocarcinoma of the rectum:
⁃ T3N0M0 - T4bN2M0